^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD122 agonist

    Related drugs:
    1d
    GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Mayo Clinic | Suspended --> Recruiting
    Enrollment open
    |
    IDH wild-type
    |
    Keytruda (pembrolizumab)
    2d
    RIOT 4B: Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors (clinicaltrials.gov)
    P1, N=10, Recruiting, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    Proleukin (aldesleukin)
    3d
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2033 --> Feb 2029 | Trial primary completion date: Jun 2031 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    9d
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    20d
    19-C-0017: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (clinicaltrials.gov)
    P1/2, N=5, Completed, National Cancer Institute (NCI) | N=70 --> 5 | Recruiting --> Completed
    Trial completion • Enrollment change • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL
    1m
    A Phase II Study of ILKN421H With Pembrolizumab in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, iLeukon Therapeutics, Inc.
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    1m
    Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P1/2, N=47, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    mTOR (Mechanistic target of rapamycin kinase)
    |
    Jingzhuda (entinostat) • Proleukin (aldesleukin)
    1m
    Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov)
    P3, N=1449, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    1m
    RIOT 4B: Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
    New P1 trial • First-in-human
    |
    Proleukin (aldesleukin)
    1m
    An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=195, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2026 --> Jun 2026 | Trial primary completion date: Dec 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)
    2ms
    A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD (clinicaltrials.gov)
    P2, N=25, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2025
    Trial completion • Trial completion date
    |
    IL2 (Interleukin 2)
    |
    Proleukin (aldesleukin)
    2ms
    A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study (2025-522427-10-00)
    P1/2, N=10, Not yet recruiting, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
    New P1/2 trial
    |
    LDH elevation
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)